Literature DB >> 27048443

Neuropsychiatric Issues in Parkinson's Disease.

Jeffrey W Cooney1, Mark Stacy2.   

Abstract

Cognitive and neuropsychiatric symptoms are common in Parkinson's Disease and may surpass motor symptoms as the major factors impacting patient quality of life. The symptoms may be broadly separated into those associated with the disease process and those that represent adverse effects of treatment. Symptoms attributed to the disease arise from pathologic changes within multiple brain regions and are not restricted to dysfunction in the dopaminergic system. Mood symptoms such as depression, anxiety, and apathy are common and may precede the development of motor symptoms by years, while other neuropsychiatric symptoms such as cognitive impairment, dementia, and psychosis are more common in later stages of the disease. Neuropsychiatric symptoms attributed to treatment include impulse control disorders, pathologic use of dopaminergic medications, and psychosis. This manuscript will review the current understanding of neuropsychiatric symptoms in Parkinson's Disease.

Entities:  

Keywords:  Cognitive impairment; Depression; Impulse control disorders; Non-motor symptoms; Parkinson’s disease; Psychosis

Mesh:

Year:  2016        PMID: 27048443     DOI: 10.1007/s11910-016-0647-4

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  162 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

2.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

Review 3.  Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis.

Authors:  Emily Bomasang-Layno; Iris Fadlon; Andrea N Murray; Seth Himelhoch
Journal:  Parkinsonism Relat Disord       Date:  2015-05-16       Impact factor: 4.891

4.  Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers.

Authors:  David Okai; Sally Askey-Jones; Michael Samuel; Sean S O'Sullivan; K Ray Chaudhuri; Anne Martin; Joel Mack; Richard G Brown; Anthony S David
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

5.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

6.  Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease.

Authors:  Alexandre Eusebio; Tatiana Witjas; Julien Cohen; Frédérique Fluchère; Elisabeth Jouve; Jean Régis; Jean-Philippe Azulay
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-02-27       Impact factor: 10.154

7.  Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up.

Authors:  P Amami; I Dekker; S Piacentini; F Ferré; L M Romito; A Franzini; E M J Foncke; A Albanese
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-07-10       Impact factor: 10.154

8.  Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.

Authors:  G Fabbrini; P Barbanti; C Aurilia; C Pauletti; G L Lenzi; G Meco
Journal:  Neurol Sci       Date:  2002-04       Impact factor: 3.307

9.  Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.

Authors:  Gaetano Salomone; Massimo Marano; Lazzaro di Biase; Jean-Marc Melgari; Vincenzo Di Lazzaro
Journal:  Parkinsonism Relat Disord       Date:  2015-07-21       Impact factor: 4.891

10.  A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

Authors:  Paul Shotbolt; Michael Samuel; Chris Fox; Anthony S David
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

View more
  21 in total

1.  Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson's Disease, and Multiple Sclerosis: Diagnosis and Treatment.

Authors:  Susan K Conroy; Katherine B Brownlowe; Thomas W McAllister
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

Review 2.  Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.

Authors:  Amanda K Kitten; Sarah A Hallowell; Stephen R Saklad; Kirk E Evoy
Journal:  Innov Clin Neurosci       Date:  2018-02-01

3.  Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an Alzheimer's Disease Model.

Authors:  Chia-Hsuan Fu; Daniel Maxim Iascone; Iraklis Petrof; Anupam Hazra; Xiaohong Zhang; Mark S Pyfer; Umberto Tosi; Brian F Corbett; Jingli Cai; Jason Lee; Jin Park; Lorraine Iacovitti; Helen E Scharfman; Grigori Enikolopov; Jeannie Chin
Journal:  Cell Rep       Date:  2019-06-25       Impact factor: 9.423

4.  Associations of Sleep Disorders With Depressive Symptoms in Early and Prodromal Parkinson's Disease.

Authors:  Jiangnan Ma; Kaixin Dou; Ruize Liu; Yajin Liao; Zengqiang Yuan; Anmu Xie
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

5.  Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms.

Authors:  Cong Yao; Lichao Niu; Yun Fu; Xu Zhu; Junfeng Yang; Peng Zhao; Xiaoxiao Sun; Yanyan Ma; Shen Li; Jie Li
Journal:  J Neural Transm (Vienna)       Date:  2021-11-27       Impact factor: 3.850

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 7.  Biological and Clinical Implications of Comorbidities in Parkinson's Disease.

Authors:  Jose A Santiago; Virginie Bottero; Judith A Potashkin
Journal:  Front Aging Neurosci       Date:  2017-12-04       Impact factor: 5.750

8.  Investigation of the Pharmaceutical Care in One Elderly Parkinson's Disease Patient with Psychotic Symptoms.

Authors:  Chun-Ping Gu; Yue-Liang Xie; Yin-Juan Liao; Cui-Fang Wu; Sheng-Feng Wang; Yu-Lu Zhou; Su-Jie Jia
Journal:  Drug Saf Case Rep       Date:  2018-04-06

9.  First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.

Authors:  Dale B Schenk; Martin Koller; Daniel K Ness; Sue G Griffith; Michael Grundman; Wagner Zago; Jay Soto; George Atiee; Susanne Ostrowitzki; Gene G Kinney
Journal:  Mov Disord       Date:  2016-11-25       Impact factor: 10.338

Review 10.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.